Literature DB >> 6148120

Bone marrow necrosis after treatment with sulphasalazine.

J E Van de Pette, D T Cunnah, T M Shallcross.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6148120      PMCID: PMC1442906          DOI: 10.1136/bmj.289.6448.798

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN: 0267-0623


× No keyword cloud information.
  4 in total

1.  Pancytopenia during salazopyrin treatment; a case report.

Authors:  P KOSKINEN
Journal:  Ann Chir Gynaecol Fenn Suppl       Date:  1954

2.  Azulfidine agranulocytosis with bone marrow, megakaryocytosis, histiocytosis and plasmacytosis.

Authors:  K Jamshidi; T Arlander; M C Garcia; H W Windschitl; W R Swaim
Journal:  Minn Med       Date:  1972-06

3.  Bone marrow necrosis. A study of seventy cases.

Authors:  C H Brown
Journal:  Johns Hopkins Med J       Date:  1972-09

4.  Toxic epidermal necrolysis, agranulocytosis and erythroid hypoplasia associated with sulphasalazine.

Authors:  J L Maddocks; D N Slater
Journal:  J R Soc Med       Date:  1980-08       Impact factor: 18.000

  4 in total
  4 in total

1.  Comparison of white blood cell dyscrasias during sulphasalazine therapy of rheumatoid arthritis and inflammatory bowel disease.

Authors:  H A Capell; T Pullar; J A Hunter
Journal:  Drugs       Date:  1986       Impact factor: 9.546

Review 2.  Sulphasalazine in arthritis--an old drug rediscovered.

Authors:  A J Taggart
Journal:  Clin Rheumatol       Date:  1987-09       Impact factor: 2.980

3.  Sulphasalazine associated pancytopenia may be caused by acute folate deficiency.

Authors:  E C Logan; L M Williamson; D R Ryrie
Journal:  Gut       Date:  1986-07       Impact factor: 23.059

4.  Mesalazine as a cause of fetal anemia and hydrops fetalis: A case report.

Authors:  Sverker Ek; Staffan Rosenborg
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.817

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.